| Gene symbol | CD40LG | Synonyms | CD154, CD40L, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq26.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD40 ligand | ||||
| Gene symbol | IL2 | Synonyms | IL-2, TCGF, lymphokine | Type of gene | protein-coding |
| Chromosome | 4 | Map location | 4q27 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | interleukin 2 | ||||
| GTO ID | GTC1218 |
| Trial ID | NCT00078520 |
| Disease | Chronic Lymphocytic Leukemia |
| Altered gene | IL-2|CD40L |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | IL-2/hCD40L gene-modified B-CLL cells |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells (CLIPA) |
| Year | 2004 |
| Country | United States |
| Company sponsor | Baylor College of Medicine |
| Other ID(s) | H11967|CLIPA |
| Vector information | |||
|
|||
| Cohort1: dose level 1 | |||||||||||
|
|||||||||||
| Cohort2: dose level 2 | |||||||||||
|
|||||||||||
| Cohort3: dose level 3 | |||||||||||
|
|||||||||||